Molecular or Metabolic Reprograming: What Triggers Tumor Subtypes?

Area of Science:

• Oncology
• Cancer Biology
• Molecular Oncology

Background:

• Tumor heterogeneity, driven by genetic, epigenetic, and metabolic variations, complicates cancer classification and treatment.
• Current tumor subtyping, primarily based on genomic or transcriptomic profiles, aids biomarker discovery but doesn't fully explain heterogeneity's origins.
• Traditional views attribute heterogeneity to "driver" oncogene mutations, but microenvironmental adaptations and metabolic shifts also play crucial roles.

Purpose of the Study:

• To review the multifaceted drivers of cancer cell-specific heterogeneity.
• To explore how genetic and metabolic factors, individually or combined, contribute to tumor heterogeneity.
• To illustrate these concepts using specific cancer examples.

Main Methods:

• Review of existing literature on tumor heterogeneity.
• Analysis of genetic, epigenetic, and metabolic influences on cancer cell phenotypes.
• Case studies of specific cancers to exemplify heterogeneity drivers.

Main Results:

• Tumor heterogeneity is influenced by interactions between cancer cells and their microenvironment.
• Metabolic switches, triggered by abnormal tumor vasculature, contribute to subtype development.
• Cancer subtypes can exhibit phenotypes resembling normal differentiated cells, stem cells, or mesenchymal cells, suggesting a role for the cell-of-origin.

Conclusions:

• Tumor heterogeneity is a complex phenomenon driven by genetic and metabolic factors, alongside microenvironmental influences.
• Understanding the interplay of these factors is essential for advancing personalized cancer diagnosis and therapy.
• The cell-of-origin may significantly impact tumor heterogeneity and subtype characteristics.